CCL25

Across TCGA pan-cancer cohorts, CCL25 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CCL25’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CCL25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCL25 is over-expressed in tumor.

LUAD, KIRC, and KICH are the cancer types where CCL25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCL25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	III,IV	+0.507	<.001	9	view →
KIRC	Male	All	+0.182	<.001	9	view →
KICH	Female	All	+0.414	<.001	7	view →
HNSC	Male	All	+0.130	.002	7	view →
LIHC	All	All	+1.257	<.001	6	view →
LUSC	All	All	+0.329	<.001	6	view →
STAD	Male	IV	+3.644	.023	2	view →
BRCA	Female	All	+0.142	.014	2	view →
ESCA	Female	All	+0.343	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CCL25–LUAD

Open the LUAD breakdown →